Postmenopausal hormone therapy and breast cancer: What is the problem?

van der Mooren, 2004, Postmenopausal hormone therapy: impact on menopause-related symptoms, chronic disease and quality of life, Drugs, 64, 821, 10.2165/00003495-200464080-00003 Shapiro, 2004, The Million Women Study: potential biases do not allow uncritical acceptance of the data, Climacteric, 7, 3, 10.1080/13697130310001651418 Beral, 2003, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study, Lancet, 362, 419, 10.1016/S0140-6736(03)14596-5 van der Mooren, 2003, Postmenopausal hormone replacement therapy in the light of the Women's Health Initiative trial, Eur J Obstet Gynecol Reprod Biol, 107, 123, 10.1016/S0301-2115(02)00413-X Rossouw, 2002, Writing group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial, JAMA, 288, 321, 10.1001/jama.288.3.321 Barrett-Connor, 1998, Hormone and nonhormone therapy for the maintenance of postmenopausal health: the need for randomized controlled trials of estrogen and raloxifene, J Womens Health, 7, 839, 10.1089/jwh.1998.7.839 Hulley, 2002, Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/progestin replacement study follow-up (HERS II), JAMA, 288, 58, 10.1001/jama.288.1.58 Chlebowski, 2003, Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial, JAMA, 289, 3243, 10.1001/jama.289.24.3243 Anderson, 2004, Women's health initiative steering committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial, JAMA, 291, 1701, 10.1001/jama.291.14.1701 Minkin, 2004, Considerations in the choice of oral vs. transdermal hormone therapy: a review, J Reprod Med, 49, 311 Kenemans, 2004, Pulsed estrogen exposure selectively modulates tissue response: a hypothesis, Gynecol Endocrinol, 18, 159, 10.1080/09513590310001653035 Kenemans, 2005, Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group, Maturitas, 51, 21, 10.1016/j.maturitas.2005.02.011 Bosman A, van der Mooren MJ, Kenemans P. Postmenopausal hormone therapy and mammographic breast density. A review. Fertil Steril, submitted for publication. Liehr, 2000, Is estradiol a genotoxic mutagenic carcinogen?, Endocrinol Rev, 21, 40, 10.1210/er.21.1.40 Clemons, 2001, Estrogen and the risk of breast cancer, N Engl J Med, 344, 276, 10.1056/NEJM200101253440407 Gadducci, 2004, Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body, Curr Opin Investig Drugs, 5, 1031 Persson, 1999, Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement, Cancer Causes Contr, 10, 253, 10.1023/A:1008909128110 Schairer, 2000, Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk, JAMA, 283, 485, 10.1001/jama.283.4.485 Porch, 2002, Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States), Cancer Causes Contr, 13, 847, 10.1023/A:1020617415381 Olsson, 2003, Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden, Cancer, 97, 1387, 10.1002/cncr.11205 Ross, 2000, Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin, J Natl Cancer Inst, 92, 328, 10.1093/jnci/92.4.328 Weiss, 2002, Hormone replacement therapy regimens and breast cancer risk(1), Obstet Gynecol, 100, 1148, 10.1016/S0029-7844(02)02502-4 Li, 2003, Relationship between long durations and different regimens of hormone therapy and risk of breast cancer, JAMA, 289, 3254, 10.1001/jama.289.24.3254 Kenemans, 2004, Oncogenetic pathways in hereditary and sporadic breast cancer, Maturitas, 49, 34, 10.1016/j.maturitas.2004.06.005 Kenemans, 2003, Breast cancer and post-menopausal hormone therapy, Best Pract Res Clin Endocrinol Metab, 17, 123, 10.1016/S1521-690X(02)00084-2 Magnusson, 1999, Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy, Int J Cancer, 81, 339, 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.0.CO;2-6 Chen, 2002, Hormone replacement therapy in relation to breast cancer, JAMA, 287, 734, 10.1001/jama.287.6.734 Newcomb, 2002, Postmenopausal estrogen and progestin use in relation to breast cancer risk, Cancer Epidemiol Biomarkers Prev, 11, 593 Stahlberg, 2004, Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe, Int J Cancer, 109, 721, 10.1002/ijc.20016 Jernstrom, 2003, A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: the women's health in the Lund area (WHILA) study (Sweden), Cancer Causes Contr, 14, 673, 10.1023/A:1025635720208 Fournier, 2005, Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort, Int J Cancer, 114, 448, 10.1002/ijc.20710 1997, Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer, Lancet, 350, 1047, 10.1016/S0140-6736(97)08233-0 Hesch, 1999, Hormonal prevention of breast cancer: proposal for a change in paradigm, Br J Obstet Gynaecol, 106, 1006, 10.1111/j.1471-0528.1999.tb08106.x Thijssen, 2004, Local biosynthesis and metabolism of oestrogens in the human breast, Maturitas, 49, 25, 10.1016/j.maturitas.2004.06.004 Gompel, 2004, Steroidal hormones and proliferation, differentiation and apoptosis in breast cells, Maturitas, 49, 16, 10.1016/j.maturitas.2004.06.009 Pasqualini, 1998, Progestins and breast cancer, J Ster Biochem Mol Biol, 65, 225, 10.1016/S0960-0760(98)00028-4 Kandouz, 1999, Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells, J Ster Biochem Mol Biol, 69, 463, 10.1016/S0960-0760(99)00069-2 Wren, 1996, Do progestogens reduce the risk of breast cancer? A review of the evidence, Menopause, 3, 4, 10.1097/00042192-199603010-00003 Spicer, 1992, The prevention of breast cancer through reduced ovarian steroid exposure, Acta Oncol, 31, 167, 10.3109/02841869209088898 Pike, 1993, Estrogens, progestogens, normal breast proliferation and breast cancer risk, Epidem Rev, 15, 17, 10.1093/oxfordjournals.epirev.a036102 Santen, 2001, Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy, J Clin Endocrinol Metab, 86, 16, 10.1210/jc.86.1.16 Sitruk-Ware, 2002, Progestogens in hormonal replacement therapy: new molecules, risks, and benefits, Menopause, 9, 6, 10.1097/00042192-200201000-00003 Eden, 2003, Progestins and breast cancer, Am J Obstet Gynecol, 188, 1123, 10.1067/mob.2003.201 Sitruk-Ware, 2004, Exogenous progestogens and the human breast, Maturitas, 49, 58, 10.1016/j.maturitas.2004.06.007 Richer, 2002, Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells, J Biol Chem, 277, 5209, 10.1074/jbc.M110090200 Antoine, 2004, Women's health initiative. Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial, Hum Reprod, 19, 741, 10.1093/humrep/deh112 Bakken, 2004, Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian women and cancer study, Int J Cancer, 112, 130, 10.1002/ijc.20389